PH12023550177A1 - Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound. - Google Patents

Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound.

Info

Publication number
PH12023550177A1
PH12023550177A1 PH1/2023/550177A PH12023550177A PH12023550177A1 PH 12023550177 A1 PH12023550177 A1 PH 12023550177A1 PH 12023550177 A PH12023550177 A PH 12023550177A PH 12023550177 A1 PH12023550177 A1 PH 12023550177A1
Authority
PH
Philippines
Prior art keywords
compound
oxadiazol
formulation
methyl
low dose
Prior art date
Application number
PH1/2023/550177A
Other languages
English (en)
Inventor
William Brian Kielbasa
Dustin James Mergott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH12023550177A1 publication Critical patent/PH12023550177A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PH1/2023/550177A 2020-07-23 2021-07-23 Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound. PH12023550177A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063055362P 2020-07-23 2020-07-23

Publications (1)

Publication Number Publication Date
PH12023550177A1 true PH12023550177A1 (en) 2024-03-18

Family

ID=77338898

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2023/550177A PH12023550177A1 (en) 2020-07-23 2021-07-23 Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound.

Country Status (21)

Country Link
US (1) US20230338349A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185291B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023535034A (cg-RX-API-DMAC7.html)
KR (1) KR20230043905A (cg-RX-API-DMAC7.html)
CN (1) CN116323604A (cg-RX-API-DMAC7.html)
AR (1) AR123031A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021312894B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000975A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186808A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000194A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000594A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000009A (cg-RX-API-DMAC7.html)
EC (1) ECSP23005057A (cg-RX-API-DMAC7.html)
ES (1) ES3039536T3 (cg-RX-API-DMAC7.html)
IL (1) IL300023A (cg-RX-API-DMAC7.html)
JO (1) JOP20230018A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000993A (cg-RX-API-DMAC7.html)
PE (1) PE20231031A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550177A1 (cg-RX-API-DMAC7.html)
TW (1) TW202220650A (cg-RX-API-DMAC7.html)
WO (1) WO2022020663A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735190B (zh) * 2016-07-22 2019-11-26 深圳市大富科技股份有限公司 Usb金属管件加工设备及其上模板
TWI654978B (zh) * 2017-01-27 2019-04-01 美商美國禮來大藥廠 5-甲基-1,2,4-二唑-3-基化合物
EP3829634A1 (en) * 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy

Also Published As

Publication number Publication date
CL2023000194A1 (es) 2023-07-21
EP4185291C0 (en) 2025-07-09
CA3186808A1 (en) 2022-01-27
AU2021312894B2 (en) 2025-09-11
PE20231031A1 (es) 2023-07-10
IL300023A (en) 2023-03-01
BR112023000975A2 (pt) 2023-02-07
KR20230043905A (ko) 2023-03-31
CN116323604A (zh) 2023-06-23
ES3039536T3 (en) 2025-10-22
ECSP23005057A (es) 2023-02-28
AR123031A1 (es) 2022-10-26
MX2023000993A (es) 2023-03-01
AU2021312894A1 (en) 2023-02-23
EP4185291A1 (en) 2023-05-31
US20230338349A1 (en) 2023-10-26
JOP20230018A1 (ar) 2023-01-23
DOP2023000009A (es) 2023-02-15
CO2023000594A2 (es) 2023-01-26
WO2022020663A1 (en) 2022-01-27
EP4185291B1 (en) 2025-07-09
JP2023535034A (ja) 2023-08-15
TW202220650A (zh) 2022-06-01

Similar Documents

Publication Publication Date Title
PE20210401A1 (es) Composiciones farmaceuticas que comprenden meloxicam
CN101031305A (zh) 类风湿性关节炎的预防和/或治疗药物
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
JP2017537164A (ja) リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
NZ597488A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
BR112018068784A2 (pt) método para o tratamento de leucemia
MY202753A (en) Griseofulvin compound and pharmaceutical use thereof
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
US20210015809A1 (en) Iloperidone metabolite for use in the treatment of psychiatric disorders
MX2010004727A (es) Nuevos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo y composicion farmaceutica de los mismos para el tratamiento de la eyaculacion precoz.
BR112023025552A2 (pt) Composições estabilizadas de apilimod e usos das mesmas
JP2010514734A (ja) 腸障害の治療のためのイソソルビドモノニトレート誘導体
FI3801515T3 (fi) 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa
MX2023000993A (es) Regimen de dosis baja y formulacion de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo.
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
US20140073591A1 (en) Mdr method and products for treating mrsa
CR20240015A (es) COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203)
MX2025009791A (es) Composicion farmaceutica de derivado de anillo heteroaromatico de benzo-nitrogeno y uso de la misma en medicina
EA201101622A1 (ru) Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования
JP2015510517A5 (cg-RX-API-DMAC7.html)
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
RU2011129815A (ru) Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи
MX2024000087A (es) Compuestos tiazol-lactama-espiroheterociclicos y sus aplicaciones.
ES2280150T1 (es) Combinacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, composicion de la misma y preparacion y uso de la misma.